We identified seven patients with variants in SOX17 not reported previously, which confirmed the initial PAH diagnosis, and we also reviewed both the clinical and molecular characteristics of our cohort and all the patients reported in the literature so far. This evidence concerns the gene SOX17 and pulmonary arterial hypertension.